Program
netarsudil
Also written as “AR-13324 Ophthalmic Solution 0.02%”, “Netarsudil Ophthalmic Solution 0.02%” and “Netarsudil ophthalmic solution 0.02%”.
Its studies are mostly in Glaucoma, Open-Angle · Glaucoma · Fuchs' Endothelial Dystrophy · Corneal Edema, led by 2 companies.
Drug pageNetarsudil: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alcon | 180 open or running | phase 4since Jan 10, 2019 | Feb 5, 2012 | none ahead |
| Price Vision Groupits history only | 20 open or running | phase 3since May 30, 2019 | May 30, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Alcon only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Feb 5, 2012.
- Jul 31, 20142 phase 3 studies in Ocular HypertensionNCT02207621, NCT02207491
- Sep 16, 2014Phase 3 study in Ocular HypertensionNCT02246764 · 93 enrolled · United States
- Mar 12, 2015Phase 1 study in Healthy SubjectsNCT02406287 · 10 enrolled · United States
- Jun 9, 2015Named netarsudilINNProposed as its International Nonproprietary Name in WHO's List 113
- Sep 16, 2015Phase 3 study in Glaucoma, Open-AngleNCT02558374 · 708 enrolled · United States
- Aug 15, 2016Phase 2 study in Ocular HypertensionNCT02874846 · 12 enrolled · United States
- Jul 12, 2017Phase 2 study in Glaucoma, Open-AngleNCT03233308 · 20 enrolled · United States
- Aug 29, 2017Phase 3 study in Glaucoma, Open-AngleNCT03284853 · 436 enrolled · Austria, Belgium, Czechia and more
- Oct 13, 2017Phase 2 study in Glaucoma, Open-AngleNCT03310580 · 42 enrolled · United States
- Jan 10, 2019Phase 4 study in Glaucoma, Open-AngleNCT03808688 · 261 enrolled · United States
- Feb 15, 2019Phase 2 study in Glaucoma, Open-AngleNCT03844945 · 215 enrolled · Japan
- Jul 31, 2020Phase 2 study in Corneal EdemaNCT04498169 · 40 enrolled · United States
- Oct 26, 2020Phase 3 study in Glaucoma, Open-AngleNCT04620135 · 245 enrolled · Japan
- Mar 7, 2022Phase 4 study in GlaucomaNCT05283395 · 136 enrolled · United States
- Jul 17, 2025Phase 3 study in Ocular HypertensionNCT07082816 · 489 enrolled · United States
TargetBeta
“Rho-associated protein kinase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| belumosudilrule | Sanofi | phase 4 | 26 |
Studies
All 18 Alcon leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07082816Ocular Hypertension · United States | 3 | Completed | Apr 6, 2026 | 489 |
| NCT05283395Glaucoma · United States | 4 | Completed | Mar 22, 2023 | 136 |
| NCT04620135Glaucoma, Open-Angle · Japan | 3 | Completed | Jul 9, 2021 | 245 |
| NCT04498169Corneal Edema · United States | 2 | Completed | Aug 11, 2021 | 40 |
| NCT03844945Glaucoma, Open-Angle · Japan | 2 | Completed | Sep 19, 2019 | 215 |
| NCT03808688Glaucoma, Open-Angle · United States | 4 | Completed | Jul 26, 2019 | 261 |
| NCT03310580Glaucoma, Open-Angle · United States | 2 | Completed | Oct 25, 2018 | 42 |
| NCT03284853Glaucoma, Open-Angle · Austria, Belgium, Czechia and more | 3 | Completed | Nov 6, 2020 | 436 |
| NCT03233308Glaucoma, Open-Angle · United States | 2 | Completed | Apr 19, 2018 | 20 |
| NCT02874846Ocular Hypertension · United States | 2 | Completed | Sep 2016 | 12 |
| NCT02558374Glaucoma, Open-Angle · United States | 3 | Completed | Dec 2016 | 708 |
| NCT02406287Healthy Subjects · United States | 1 | Completed | Apr 2016 | 10 |
| NCT02246764Ocular Hypertension · United States | 3 | Completed | Dec 2016 | 93 |
| NCT02207621Ocular Hypertension · United States | 3 | Completed | Mar 2016 | 756 |
| NCT02207491Ocular Hypertension · United States | 3 | Completed | Mar 2015 | 411 |
| NCT01997879Healthy · United States | 1 | Completed | Nov 2013 | 18 |
| NCT01731002Ocular Hypertension · United States | 2 | Completed | May 2013 | 224 |
| NCT01528787Ocular Hypertension · United States | 2 | Completed | Jul 2012 | 85 |
How it is read
Names in the registry
- “AR-13324 Ophthalmic Solution 0.02%”, 7 entries
- “Netarsudil Ophthalmic Solution 0.02%”, 3 entries
- “Netarsudil ophthalmic solution 0.02%”, 2 entries
- “Netarsudil Ophthalmic”, 2 entries
- “AR-13324 Ophthalmic Solution 0.04%”, 2 entries
Conditions, from the studies’ own filings
- Glaucoma, Open-Angle, 13 studies
- Glaucoma, 2 studies
- Fuchs' Endothelial Dystrophy, 2 studies
- Corneal Edema, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.